Prothena (PRTA) News

Major Insider Move Signals Growing Confidence in Prothena Shares

TipRanksAug 22 10:09

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Prothena (PRTA)

TipRanksAug 15 00:10

BofA Securities Maintains Prothena(PRTA.US) With Sell Rating

BofA Securities analyst Tazeen Ahmad maintains $Prothena(PRTA.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 58.9% and a total average return of 5.9% over the

Futu NewsAug 14 23:33

Piper Sandler Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $36

Piper Sandler analyst Yasmeen Rahimi maintains $Prothena(PRTA.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 49.8% and a

Futu NewsAug 7 23:31

Piper Sandler Sticks to Its Buy Rating for Prothena (PRTA)

TipRanksAug 7 23:27

RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $13

RBC Capital analyst Brian Abrahams maintains $Prothena(PRTA.US)$ with a hold rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 56.1% and a

Futu NewsAug 7 19:36

Analyst Reiterates Buy on Prothena, Citing Disciplined Capital Strategy and Undervalued TTR Franchise With Unchanged $30 Price Target

TipRanksAug 7 18:45

Express News | Prothena: May Earn $55 Mln Clinical Milestone Payment if Bristol Myers Squibb Decides to Advance Prx019 ; Bms Decision Expected Year End 2026

BreakingsAug 7 05:10

Prothena | 10-Q: Q2 2026 Earnings Report

SECAug 7 04:20

Prothena Corp Q2 EPS $0.36 Beats $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate

Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.09) by 500 percent. This is a 120.81 percent increase over losses of $(1.73)

BenzingaAug 7 04:20

Prothena | 8-K: Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights

SECAug 7 04:17

Express News | Prothena Q2 Operating Expenses USD 22.111 Million

BreakingsAug 7 04:05

Express News | Prothena Q2 Collaboration Revenue USD 1.01 Million

BreakingsAug 7 04:05

Express News | Prothena Q2 Net Income USD -18.583 Million

BreakingsAug 7 04:05

Prothena 2Q Loss $18.6M >PRTA

Prothena 2Q Loss $18.6M >

Dow JonesAug 7 04:05

Prothena Q2 2026 Earnings Preview

Seeking AlphaAug 6 05:35

Earnings Preview: Prothena to Report Financial Results Post-market on August 06

$Prothena(PRTA.US)$ is scheduled to release its financial results post-market on August 06 ET. Earnings PreviewAnalysts estimate $Prothena(PRTA.US)$ to post revenue of USD421.67K for 2026Q2, down 90.4

Futu NewsAug 1 09:00

Express News | Prothena to Report Second Quarter 2026 Financial Results on August 6

BreakingsJul 31 04:05

Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity

TipRanksJul 24 20:25